Vonoprazan-related adverse events: a pharmacovigilance study based on the FDA adverse event reporting system

作者：Yali Zhong, Chuan Hou, Jie Zhang, Wang Li, Dongmei Xiong, Zhong Huang, Xiaobin Luo · 发表于：Frontiers in Medicine · 年份：2025 · DOI：10.3389/fmed.2025.1688914 · 被引用次数：2 · 研究领域：Pharmacovigilance and Adverse Drug Reactions、Drug-Induced Adverse Reactions、Respiratory and Cough-Related Research

This study comprehensively evaluated the safety profile of Vonoprazan using data from the FDA Adverse Event Reporting System (FAERS) from the first quarter (Q1) of 2023 through the first quarter (Q1) of 2025. This analysis was restricted to real-world reports collected after the U. S. approval of vonoprazan, to better reflect its current clinical use pattern in the United States. Reports in which Vonoprazan was designated as the primary suspect(PS) drug were systematically extracted, and duplicate entries were removed using MySQL(version 8.0.42). Adverse events were coded in according tothe Medical Dictionary for Regulatory Activities (MedDRA, version 24.0). To detect potential safety signals, four disproportionality methods were applied: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS). Differences between serious and non-serious adverse events were further examined using Pearson's chi-square test and Fisher's exact test. Temporal patterns of adverse event occurrence were evaluated using Time-to-Onset (TTO) analysis and Weibull Shape Parameter (WSP) modeling. In total, 978 vonoprazan-related cases were included; females accounted 62.0% of reports, and 34.3% of events were classified as serious. Forty seven preferred terms (PTs) met predefined signal criteria, and 16 of these, such as facial paralysis and cholecystitis, were not listed in the current U. S. FDA p...